BenevolentAI Group: Analyst / Investor Event and Interim Results

2022-09-16

财报合作

LONDON, Sept. 16, 2022 /PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.

The event will be held in person at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London, EC1A 4HD, United Kingdom) and will also be accessible via webcast with a presentation recording made available on the Company's website shortly afterwards.

At the event, BenevolentAI's executive leadership team will lead sessions about the Company's approach and technology and its positioning within the wider AI drug discovery market, as well as talking about the Company's pipeline and business model. The event will also include an overview of BenevolentAI's interim results for the period ended 30 June 2022. Presentations will be given by BenevolentAI's executive leadership team in addition to Professor Tom MacDonald of Immunology at Barts and the London School of Medicine and Dentistry, Queen Mary, University of London.

The full agenda is as follows:

To register your interest in attending either in person or virtually, please contact FTI Consulting at [email protected] or +44 (0) 20 3727 1000.

ABOUT BENEVOLENTAI

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The Benevolent Platform™ powers a growing in-house pipeline of over 20 disease programmes, spanning from target discovery to clinical studies, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

SOURCE BenevolentAI

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构